key: cord-0788353-2ooi24d9 authors: Piec, Isabelle; Cook, Laura; Dervisevic, Samir; Fraser, William D; Ruetten, Scott; Berman, Marvin; English, Emma; John, W Garry title: Age and vitamin D affect the magnitude of the antibody response to the first dose of the SARS-CoV-2 BNT162b2 vaccine date: 2022-03-16 journal: Curr Res Transl Med DOI: 10.1016/j.retram.2022.103344 sha: 8e9c90c19098bcc9ff261b505cf6eab87a9cb762 doc_id: 788353 cord_uid: 2ooi24d9 BACKGROUND: Most approved vaccines utilise a two-dose strategy. To enable larger groups of patients to receive the first dose, the UK government increased the gap between the two doses from three to twelve weeks. Here we report on the immunogenicity of the first dose, including effect of age and vitamin D status on these levels over an 8 week-period. METHODS: Blood samples were collected from healthcare workers (HCW) receiving their first BNT162b2 vaccine dose between January and February 2021. Antibody (Ab) production was measured, prior to and weekly for 4 weeks post immunization, and a final measurement was performed at 8 weeks. Serum vitamin D concentrations were also measured at baseline. FINDINGS: Immunization of 97 HCW induced an Ab response that peaked 3•2 weeks post immunization to decrease thereafter. Ab levels remained positive at 8 weeks. IgG peak concentration was negatively associated with age (β=-0•440, p<0.001). Response to immunization was also significantly affected by vitamin D status (p=0•022), on average 29•3% greater peak value in individuals with 25(OH)D>50nmol/L. No other variable showed significant effect. INTERPRETATION: The first dose of BNT162b2 produced Ab levels that remained positive after 8 weeks. Peak was greater in younger subjects and 25(OH)D>50nmol/L was beneficial. Booster campaigns should take into consideration vitamin D status which is at its highest following a period of sunshine exposure or following oral supplementation (400-1000IU daily). FUNDING: Abbott Diagnostics Ltd supplied the kits used to quantify the anti-SARS -CoV-2 Spike IgG and technical support as well as provided financial support for sample collections. As SARS-CoV-2 continues to affect the world, large scale immunization programmes are having a significant impact on hospitalization rates and mortality. Pfizer/BioNTech BNT162b2, thereafter BNT162b2, was the first COVID-19 vaccine authorized for use in the UK 1 . The decision of the UK government to extend the recommended interval between the two doses from three to 12 weeks 2, 3 was received with scepticism around the potential loss or degradation of the immune response, especially as trial data was based on the shorter interval of three weeks. Ageing is known to be accompanied by dysregulation of immune system functions and a higher incidence with more severe outcomes of respiratory infections such as pneumonia 4 and an increased occurrence of cancers 5 and autoimmune diseases 6 . A number of publications have suggested a beneficial effect of vitamin D supplementation against severe COVID-19 symptoms 7 and supplementation was recommended by the UK government in specific high risk population groups 8 . Moreover, vitamin D, specifically its active form 1-alpha,25-dihydroxyvitamin D3, is known to modulate the innate and adaptive immune response 9, 10 and vitamin D is often used as a candidate hormone in improving immune response 11, 12 . In this study we followed the anti-SARS-CoV-2 Spike IgG production in a cohort of health care workers (HCW), over eight weeks after receiving the first dose of the BNT162b2 mRNA vaccine, using a newly developed and validated assay that can quantify the antibody concentrations. We investigated the relationship between IgG response post immunization and 25(OH)D concentrations, age and other demographics. All participants provided written informed consent. The study was approved by the Health Research Authority Health and Care Research Wales ethical committee (IRAS#292799). We assessed the immune response generated after immunization with BNT162b2 (Pfizer Inc. [New York, USA] and BioNTech SE [Mainz, Germany]) in a cohort of 105 HCW immunized at the Norfolk and Norwich University Hospital (Norwich, UK) in January 2021. Serum samples were taken at baseline (within a week prior to immunization, Bo), followed by weekly (7±1 days) sampling for four weeks (W1 to W4) after the first vaccine dose was administered and at week eight (W8), prior to administration of the second dose. A questionnaire provided self-declared demographic characteristics (age, gender, ethnicity), clinical characteristics (weight, height, health issues, current medication), and the presence of COVID-19 symptoms within the last six months. Biochemistry Abbott Alinity i system Immunoassays (Abbott Park, IL, USA) were used to measure SARS-CoV-2 antispike IgG (quantitative) and anti-nucleocapsid IgG (qualitative) in serum. Quantitative results are reported in AU/mL and the positivity cut-off as per manufacturer's instruction is 50AU/mL. Qualitative results are positive for index results above 1·4, the index is calculated based on the optical density of the sample in reference to the optical density of the calibrator using the equation OD sample /OD cal . These assays were previously validated 13, 14 . Baseline 25(OH)D was measured by LC-MS/MS and 1,25(OH) 2 D was measured by Immunoassay (DiaSorin, Dartford, UK). All statistical analyses and graphical representation were performed using IBM SPSS Statistics 25.0.0.1 and/or GraphPad Prism version 9.0 (GraphPad Software, Inc., USA). Statistical significance was considered as a two-tailed P value <0·05 (*P<0·05; **P<0·01 and ***P<0·001). IgG concentrations over time were analyzed using a mixed model paired test. Non normally distributed variables were LN transformed. Increase (peak) and decrease of antibody (peak-W8) concentrations were analyzed by A total of 105 HCW provided at least one blood sample for antibody testing prior to immunization (baseline, Bo). After excluding HCW who had a measurable antibody baseline (58·1 to 5496·9 AU/mL, n=6) and those who did not seroconvert after immunization (anti-Spike IgG concentration not reaching values greater than 22·0 AU/mL, n=2), the remaining 97 HCW (mean [ In all the remaining 97 HCW, the antibody concentration increased and peaked on average at 3·2 weeks (95% CI, 3·1-3·3). The concentrations of anti-Spike IgG did not change significantly at week 1 (p=0·3896) but increased sharply and significantly thereafter (Fig 1) (p<0·0001). IgG peak concentrations were variable and ranged between 161-12020 AU/mL. Peaks were followed by a steady decrease in antibody concentrations over the following weeks (table 2) . Anti-nucleocapsid IgG were measured and not detected in any of these participants, confirming Ab response was not due to natural infection. The group was composed of 79% females and 90% of participants were white, sex and ethnicity were therefore not included as criteria. BMI showed no association with the production of antibody (p=0·339) or with the decrease in antibody concentrations (p=0·574). The peak in anti-Spike IgG was strongly negatively associated with age (continuous variable p<0·001). For visualisation purposes, we presented age by decile (Fig 2) . At W8, the concentrations of anti-Spike At baseline, only 34% of HCW had adequate 25(OH)D, 27·9% had deficient and 38·1% insufficient level. As a continuous variable, 25(OH)D showed association (p=0·019) with the production of Ab. However, there was a strong positive association between production of Ab and the categorised variable deficient/insufficient/replete (p=0·034) (Fig 3) and an even stronger association when only using below and above 50nmol/L (p=0·013), mirroring clinical cut points. Loss of antibody after peak (peak -W8 concentrations) was also associated with 25(OH)D concentrations (p=0·040). No association was observed between 1,25(OH) 2 D concentrations and peak IgG concentrations nor loss of IgG (p=0·104 peak; p=0·536 drop). In this study the initial dose of BNT162b2 triggered a serological response that is likely able to protect the recipients against COVID-19 infection by priming the immune system. The older the subjects in this group the lower was the peak Ab response, however at W8, concentrations were similar between all ages. The age range of our subjects reflects the age of HCW currently employed with low incidence of very elderly subjects. Shroti et al., 16 reported an age dependent increase in the proportion of people who seroconvert over time. With a mean age of participants significantly higher than in our study, the study adds to the validity of our data suggesting that the effect of age is across the lifespan. Circulating 25(OH)D concentrations are used as marker of vitamin D status. They are at their lowest during winter and spring seasons, lower in BAME and lower at higher latitudes. Across the UK, the expected prevalence of deficiency (<25nmol/L) in winter is 23·1% 17 and 10% in Caucasian women 18 . Almost a third (27·9%) of our group comprising close to 90% Caucasian women was 25(OH)D deficient, This is a single-centre study with a limited number of participants and is strongly biased towards female and white participants which might limit the generalizability of the findings. Conclusions Amongst HCW in a single UK centre, antibody profile after a first injection of BNT162b2 was associated with age and vitamin D status at baseline. Younger people were reaching higher peaks but decreasing to similar levels as older after 8 weeks. Vitamin D was also beneficial to the production of antibodies. Two of the authors (SR and MB) are employees of Abbott Diagnostics Ltd who supplied the kits used to quantify the anti-SARS -CoV-2 Spike IgG and technical support as well as provided financial support for sample collections. All other authors have no conflict of interest. Safety and Immunogenicity of Two RNA-Based Covid-19 New England Journal of Medicine2020 Optimising the covid-19 vaccination programme for maximum short-term impact PF-07302048). Vaccines And Related Biological Products Advisory Committee briefing document The impact of influenza on the health and health care utilisation of elderly people. Vaccine Age and cancer risk: a potentially modifiable relationship. American journal of preventive medicine Autoimmunity in the Elderly: Insights from Basic Science and Clinics -A Mini-Review Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19 Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile Vitamin D supplementation to prevent infections: a sub-study of a randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438) Performance of SARS-CoV-2 serology tests: Are they good enough? Performance of the Abbott SARS-CoV-2 IgG II Quantitative antibody assay including the new Variants of Concern (VOC 202012/V1 (UK) and VOC 202012/V2 (South Africa)): And first steps towards global harmonization of COVID-19 antibody methods Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors -a prospective community cohort study (Virus Watch) Distribution of vitamin D status in the UK: a crosssectional analysis of UK Biobank Vitamin D deficiency in UK South Asian Women of childbearing age: a comparative longitudinal investigation with UK Caucasian women Impact of Vitamin D Supplementation on Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized Placebo-Controlled Trial Vitamin D and 1,25(OH)2D regulation of T cells Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients The authors would like to thank Lucy Browne and Cameron Cornwell for they help with sampling our HCW. We also would like to thank Rachel Dunn for the analysis of 25(OH)D and Lee Shepstone for his advice on statistics. Finally, we wish to thank Abbott Diagnostics Ltd for their continuous technical support and providing the kits necessary to perform this study.